iOS
Android
Facebook
WhatsApp
Twitter
Rovista EZ contains rosuvastatin calcium and ezetimibe. Rosuvastatin is a 3-hydroxy-3methylglutaryl coenzyme A (HMG CoA)-reductase inhibitor. Ezetimibe is a dietary cholesterol absorption inhibitor. Rovista EZ (Rosuvastatin + Ezetimibe) is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolemia where use of combination product is appropriate in patients: • not appropriately controlled with rosuvastatin or ezetimibe alone; or • already treated with rosuvastatin and ezetimibe
Rosuvastatin 20mg and ezetimibe 10mg
Rovista EZ (Rosuvastatin + Ezetimibe) can be administered within the dosage range of 5mg+10mg to 40mg+10mg as a single daily dose. The recommended starting dose is 5mg+10mg or 10 mg+10mg once per day. The combination of Rosuvastatin + Ezetimibe can be administered at any time of the day, with or without food. Each tablet should be taken with water at the same time daily and is not to be chewed or crushed. Therapy should be individualized according to the target lipid levels, the recommended goal of therapy, and the patient's response. The dose should also take into account the potential risk for adverse reactions. A dose adjustment can be made after 4 weeks of therapy where necessary. The usual maximum dose is 20mg+10mg once per day. This combination product is not indicated for first-line use.
KES 2,787.00
Delivery within 4 hours on all orders placed between 8:00 AM & 8:00 PM
